S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: Phase II trial

BMC Cancer

Volumn 13, Issue , 2013, Pages 1-7

  Moon, Yong W ^a,c   Lee, Soohyeon ^a   Park, Byeong Woo ^b   Kim, Eun Kyung ^b   Kim, Seung I ^b   Koo, Ja S ^b   Park, Seho ^b   Kim, Min J ^b   Chung, Hyun C ^a   Kim, Joo Hang ^a   Sohn, Joohyuk ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Docetaxel; Neoadjuvant chemotherapy; Pathological complete response; S 1

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; OTERACIL; S 1 (COMBINATION); TAXOID; TEGAFUR;

ADJUVANT THERAPY; ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EPIGASTRIC PAIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LYMPH NODE METASTASIS; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; STOMATITIS; TUMOR VOLUME; VOMITING; BREAST TUMOR; CANCER STAGING; DRUG COMBINATION; INDUCTION CHEMOTHERAPY; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG COMBINATIONS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; OXONIC ACID; RISK FACTORS; TAXOIDS; TEGAFUR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84890120828     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-583     Document Type: Article

References (21)

1. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24(12):1940-1949. 10.1200/JCO.2005.02.6187, 16622270.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Fisher ER, Wickerham DL, Wolmark N, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15(7):2483-2493.
3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26(5):778-785. 10.1200/JCO.2007.15.0235, 18258986.
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17(2):460-469.
5. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996, 7(5):548-557. 10.1097/00001813-199607000-00010, 8862723.
6. Satoh T, Sakata Y. S-1 for the treatment of gastrointestinal cancer. Expert Opin Pharmacother 2012, 13(13):1943-1959. 10.1517/14656566.2012.709234, 22860709.
7. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009, 39(1):2-15. 2639406, 19052037.
8. Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, et al. A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004, 11(2):194-202. 10.1007/BF02968301, 15550867.
9. Suto A, Kubota T, Fukushima M, Ikeda T, Takeshita T, Ohmiya H, Kitajima M. Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice. Oncol Rep 2006, 15(6):1517-1522.
10. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, Roh JK, Noh SH, Chung HC. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer 2011, 117(10):2050-2057. 10.1002/cncr.25729, 21523716.
11. Oki Y, Hirose T, Yamaoka T, Kusumoto S, Shirai T, Sugiyama T, Okuda K, Nakashima M, Murata Y, Ohmori T, et al. Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2011, 67(4):791-797. 10.1007/s00280-010-1382-1, 3064900, 20556612.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. 10.1016/j.ejca.2008.10.026, 19097774.
13. Von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005, 23(12):2676-2685.
14. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823. 10.1200/JCO.2002.09.002, 12065558.
15. Von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010, 28(12):2015-2023. 10.1200/JCO.2009.23.8303, 20308671.
16. Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 2012, 366(4):310-320. 10.1056/NEJMoa1111097, 3401076, 22276821.
17. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012, 30(1):11-18. 10.1200/JCO.2011.35.4639, 22105826.
18. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-2334. 10.1158/1078-0432.CCR-06-1109, 17438091.
19. Bang YJ, Kang WK, Kang YK, Kim HC, Jacques C, Zuber E, Daglish B, Boudraa Y, Kim WS, Heo DS, et al. Docetaxel 75 mg/m (2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002, 32(7):248-254. 10.1093/jjco/hyf057, 12324575.
20. Zang DY, Yang DH, Lee HW, Hwang SW, Song HH, Jung JY, Kwon JH, Kim HJ, Kim JH, Park SR, et al. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol 2009, 63(3):509-516. 10.1007/s00280-008-0768-9, 18481067.
21. Jeung HC, Rha SY, Kim HK, Lim HY, Kim S, Kim SY, Gong SJ, Park CH, Ahn JB, Noh SH, et al. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist 2007, 12(5):543-554. 10.1634/theoncologist.12-5-543, 17522242.